Skip to content
As part of BIO’s March Patient Advocacy Coffee Chat, Thomas Heymann, President & CEO of Sepsis Alliance, spoke about sepsis—a life-threatening condition caused by […]
Sepsis and AMR: Understanding the connection and the growing threat to public health Read More »
Despite women making up half the population, women’s health has historically been “woefully underfunded,” accounting for less than 5% of products in the biotech
Women’s History Month: What’s the story with women’s health investment? Read More »
The Food and Drug Administration’s (FDA) Rare Pediatric Disease Priority Review Voucher (PPRV) Program was top of mind during BIO’s March Patient Advocacy Coffee
March 8th is International Women’s Day and to mark the occasion, Bio.News is exploring an under researched field of women’s health – autoimmune diseases
International Women’s Day: Improving women’s health by addressing autoimmune disease Read More »
“Kidney disease is a major and growing public health concern,” LaVarne A. Burton, American Kidney Fund President and CEO, said in an interview with
Kidney Action Week: 4 things you need to know about kidney disease Read More »
The Centers for Medicare & Medicaid Services (CMS) recently announced the 2025 selection of 15 drugs covered under Medicare Part D for price “negotiations”
The role of the patient voice in CMS drug price ‘negotiation’ Read More »
February 28 is Rare Disease Day, and in observance, the Biotechnology Innovation Organization (BIO) is highlighting how it is working with member companies to
BIO celebrates release of FDA Rare Disease Innovation Hub 2025 strategic plan Read More »
Drug development in the rare disease space has seen a vast amount of innovation in recent years, with a number of groundbreaking therapies coming
Goodwin Rare Disease Symposium: ‘So much opportunity, so much unmet need’ Read More »
The U.S. Food and Drug Administration’s Accelerated Approval Pathway enables the timely development of treatments for severely ill patients who have few if any
BIO coffee chat focuses on reimbursement for Accelerated Approval Pathway drugs Read More »
Despite a pressing demand, schizophrenia has had limited treatment. “Roughly 1% of the entire world population has schizophrenia,” said Boobalan Pachaiyappan, Managing Director and
BIO CEO 2025: New solution for the challenge of schizophrenia Read More »
